Victoria Socha

DocwireNews

Masatomo Ogata, MD, and colleagues previously reported results of a study examining the short-term efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHi) for the treatment of post-kidney-transplant anemia. During a poster session at the American Society of Nephrology Kidney Week 2022, they presented results of re-analyzation of HIF-Phi for posttransplant anemia in the context of longer follow-up using a different class of HIF-PHi.The poster was titled Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Treatment of Post Kidney Transplant Anemia.The current analysis included nine kidney transplant recipients at Marianna University School of Medicine, Kawasaki, Japan. In erythropoiesis-stimulating agent (ESA) na&iuml;ve patients, the indication of HIF-Phi was hemoglobin level below 11.0 g/dL; among patients treated with an ESA, the indication was hemoglobin level below 13.0 g/dL. Either roxadustat or enarodustat was used according to the recommended dose adjustments to achieve target hemoglobin levels between 11.0 and 13.0 g/dL.Patients were monitored for anemia-related parameters, including hemoglobin, total iron-binding capacity, and ferritin levels, in addition to low-density lipoprotein (LDL) cholesterol up to 14 months. Adverse events of interest were thromboembolic events and malignancy.Of the nine kidney transplant recipients, six were prescribed roxadustat and three were prescribed enarodustat. Mean estimated glomerular filtration rate in the total cohort was 25.6 mL/min/1.73 m2. Most of the transplant recipients showed an increase or maintained their hemoglobin levels from baseline; two kept their hemoglobin levels below the target range.A few of the transplant recipients treated with roxadustat showed rapid increase and decrease in hemoglobin and ferritin levels, respectively, despite being prescribed the recommended initial dose. Only those in the roxadustat group had a drop in LDL cholesterol levels. There were no adverse events reported during the observation period.&ldquo;Based on the recommended dose of HIF-PHi, treatment with roxadustat resulted in a more rapid increase in hemoglobin levels along with a stronger improvement in iron utilization as compared to that seen in treatment with enarodustat,&rdquo; the researchers said. &ldquo;For posttransplant anemia, HIF-PHi would be safe and useful in clinical use.&rdquo;Source: Ogata M, Miyauchi T, Murata M, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitors for treatment of post kidney transplant anemia. FR-PO832. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2022; November 4, 2022; Orlando, Florida.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Longer-Term Results With HIF-PHi for Post-Kidney-Transplant Anemia

ASN Kidney Week 2022

Masatomo Ogata, MD, and colleagues previously reported results of a study examining the short-term efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHi) ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe